IriSys' Deal with National Cancer Institute Doubles to $6 MillionThursday, April 20, 2017
Local drugmaker IriSys LLC announced Thursday that its contract with the National Cancer Institute (NCI) has doubled in value from $3 million to $6 million.
Under the terms of the five-year contract, IriSys will develop and manufacture new drugs for use in clinical trials supported by NCI. The deal was first initiated in June 2015 and will be in effect through June 2020.
Making drug formulations for clinical trials and pharmaceutical companies is one of IriSys’ services. The company makes materials in all dosage forms, including tablets and capsules, as well as liquids, injectables, and topical ointments here in San Diego.